Hussman Strategic Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Hussman Strategic Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-210,000	Closed	-$1.76M	–	217
2025 Q1	$1.76M	Sell	210,000 -42,000	-17%	-$351K	0.43%	92
2024 Q4	$2M	Buy	252,000 +42,000	+20%	+$352K	0.59%	63
2024 Q3	$1.75M	Buy	210,000 +63,000	+43%	+$493K	0.43%	108
2024 Q2	$933K	Buy	+147,000	New	+$933K	0.26%	148
2023 Q2	–	Sell	-180,000	Closed	-$250K	–	296
2023 Q1	$250K	Hold	180,000	–	–	0.04%	292
2022 Q4	$358K	Hold	180,000	–	–	0.06%	271
2022 Q3	$364K	Hold	180,000	–	–	0.06%	264
2022 Q2	$572K	Hold	180,000	–	–	0.1%	250
2022 Q1	$751K	Hold	180,000	–	–	0.15%	210
2021 Q4	$862K	Hold	180,000	–	–	0.19%	173
2021 Q3	$961K	Hold	180,000	–	–	0.21%	163
2021 Q2	$922K	Hold	180,000	–	–	0.19%	191
2021 Q1	$1.21M	Buy	180,000 +57,000	+46%	+$316K	0.25%	158
2020 Q4	$562K	Buy	123,000 +21,000	+21%	+$93.1K	0.15%	221
2020 Q3	$396K	Buy	+102,000	New	+$436K	0.1%	225
2018 Q4	–	Sell	-125,000	Closed	-$2.77M	–	264
2018 Q3	$2.77M	Sell	125,000 -75,000	-38%	-$1.58M	0.8%	41
2018 Q2	$3.28M	Buy	+200,000	New	+$3.51M	0.88%	34

Other funds holding AMRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hussman Strategic Advisors's AMRX Position: Q2 2025 in Review

Hussman Strategic Advisors sold out of Amneal Pharmaceuticals (AMRX) in Q2 2025, closing a stake of 210,000 shares — an estimated $1.76M sold.

Hussman Strategic Advisors first reported a position in AMRX in Q2 2018 and held it in 17 quarters. The position peaked at $3.28M in Q2 2018. 241 funds tracked by Wall St. Rank hold AMRX as of Q2 2025.

Hussman Strategic Advisors reported no remaining Amneal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Hussman Strategic Advisors sold 210,000 Amneal Pharmaceuticals shares in Q2 2025, an estimated $1.76M.
Hussman Strategic Advisors first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 17 quarters.
Hussman Strategic Advisors's Amneal Pharmaceuticals position peaked at $3.28M in Q2 2018.
241 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2025.

Based on Hussman Strategic Advisors's 13F filing for Q2 2025, filed 5 Aug 2025.